Nelson Peltz
Nelson Peltz's Portfolio
Last Updated on 8/14/08 @ 12:14pm
| Ticker | # of Shares | Price | Value | |
|---|---|---|---|---|
| SPY | N/A | $115.30 | N/A | |
| KFT | 31,094,639 | $29.63 | $921,334,154 | |
| TIF | 10,067,240 | $47.25 | $475,677,090 | |
| HNZ | 8,928,018 | $47.36 | $422,830,933 | |
| DPS | 4,662,758 | $36.18 | $168,698,585 | |
| CAKE | 3,228,424 | $27.14 | $87,619,428 | |
| WYE | 1,535,633 | $50.39 | $77,380,547 | |
| HANS | 1,292,166 | $42.82 | $55,330,549 | |
| TGT | 937,172 | $53.30 | $49,951,268 | |
| PFCB | 1,060,875 | $43.89 | $46,561,804 | |
| View Additional Portfolio Information » | ||||
*shorted stocks appear in red
Nelson Peltz in an American billionaire. He is Chairman of Triarc Companies (NYSE: TRY), the franchisor of the Arby's restaurant in the US and Canada. Peltz is also CEO and Founding Partner of Trian Fund Management, L.P, a New-York based investment company.
Peltz is a board member at H.J. Heinz (NYSE: HNZ), which was awarded to him after he pushed the company for changes.
In 2008, Peltz reached a deal to acquire Wendy's (NYSE: WEN).
Peltz also owns large stakes in Kraft Foods (NYSE: KFT), Cheesecake Factory (Nasdaq: CAKE), Tiffany & Co. (NYSE: TIF) and Cadbury-Schweppes (NYSE: CSG). In 2007, Cadbury-Schweppes announced plans to split-off and sell their Americas Beverages unit following Peltz' involvement in the stock, but a sale could not be reached due to the credit crunch.
StreetInsider.com Pre-Open Movers:
Pharmacopeia (Nasdaq: PCOP) 42% HIGHER; announced that PS433540, its first-in-class Dual Acting Receptor Antagonist (DARA), showed statistically significant blood pressure reductions in a Phase 2a study in patients with mild to moderate hypertension.
Dynavax Technologies Corporation (Nasdaq: DVAX) 18% LOWER; reported primary endpoint data from a chamber study of TOLAMBA that showed a measurable clinical benefit, reducing total nasal symptom score by 41% vs. placebo in 253 patients in the intent-to-treat population (p=0.09) and by 51% vs. placebo in 222 patients in the per-protocol population (p=0.053). Statistical significance on the primary efficacy endpoint (change in TNSS for the intent-to-treat population) for this Phase 2b environmental exposure chamber study was not achieved.
Noah Education Holdings, Ltd. (NYSE: NED) 17% HIGHER; reports Q3 revenues rose 8.5% to US$26.3 million and EPS of $0.20, veruss $0.05 last year. Noah expects its total net revenue for the fourth quarter of fiscal ...
StreetInsider.com After-Hours Movers:
Noah Education Holdings, Ltd. (NYSE: NED) 17% HIGHER; reports Q3 revenues rose 8.5% to US$26.3 million and EPS of $0.20, veruss $0.05 last year. Noah expects its total net revenue for the fourth quarter of fiscal year 2008 (April 1, 2008 to June 30, 2008) to grow in the range of 16% to 18%, compared to the corresponding period last year. Noah expects net income growth in the fourth fiscal quarter 2008 in the range of 350% to 400%, as compared to the corresponding period last year. In addition, The Company has raised it forecast for total net profit for full fiscal year 2008 to be in the range of RMB128 million to RMB130 million. This forecast reflects Noah's ...
